|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
TWI635098B
(zh)
*
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-CD3 antibodies and methods of using them
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI701042B
(zh)
*
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
EP3699195A3
(en)
|
2014-03-28 |
2020-11-04 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
|
KR102614189B1
(ko)
*
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
|
RU2726446C2
(ru)
|
2014-11-24 |
2020-07-14 |
Регенерон Фармасьютикалз, Инк. |
Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10544220B2
(en)
|
2015-01-08 |
2020-01-28 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
WO2016161010A2
(en)
|
2015-03-30 |
2016-10-06 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
EA039429B1
(ru)
*
|
2015-05-13 |
2022-01-26 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения опухолей с применением биспецифического антитела cd3xcd20
|
|
DK3310814T5
(da)
|
2015-06-16 |
2024-10-07 |
Hoffmann La Roche |
Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse
|
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
JP6837436B2
(ja)
*
|
2015-07-10 |
2021-03-03 |
中外製薬株式会社 |
内因性ｃｄ３遺伝子をヒトｃｄ３遺伝子に置換した非ヒト動物
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
AU2016325630B2
(en)
|
2015-09-23 |
2022-11-17 |
Regeneron Pharmaceuticals, Inc. |
Optimized anti-CD3 bispecific antibodies and uses thereof
|
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
AU2016378573A1
(en)
*
|
2015-12-22 |
2018-07-19 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
|
|
LT3394103T
(lt)
*
|
2015-12-22 |
2023-09-11 |
Regeneron Pharmaceuticals, Inc. |
Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
|
|
EP3402825A1
(en)
|
2016-01-12 |
2018-11-21 |
Crescendo Biologics Limited |
Molecules that bind prostate specific membrane antigen (psma)
|
|
SG11201807885PA
(en)
|
2016-04-20 |
2018-10-30 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
|
BR112018071285A2
(pt)
|
2016-04-20 |
2019-02-12 |
Regeneron Pharma |
célula, conjunto de vetores, vetor, sistema, e, método
|
|
GB201607968D0
(en)
|
2016-05-06 |
2016-06-22 |
Crescendo Biolog Ltd |
Chimeric antigen receptor
|
|
TWI910495B
(zh)
|
2016-05-13 |
2026-01-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
WO2017210485A1
(en)
*
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
|
|
JP7010854B2
(ja)
|
2016-06-14 |
2022-01-26 |
ゼンコア インコーポレイテッド |
二重特異性チェックポイント阻害剤抗体
|
|
KR20250175345A
(ko)
*
|
2016-06-21 |
2025-12-16 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
CN109715663B
(zh)
|
2016-06-28 |
2022-11-25 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
WO2018038046A1
(ja)
|
2016-08-22 |
2018-03-01 |
中外製薬株式会社 |
ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
PE20241349A1
(es)
*
|
2016-09-14 |
2024-07-03 |
Teneobio Inc |
Anticuerpos de union a cd3
|
|
JP7066690B2
(ja)
*
|
2016-09-23 |
2022-05-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｍｕｃ１６（ムチン１６）抗体
|
|
MY203000A
(en)
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
JP7784795B2
(ja)
*
|
2016-11-15 |
2025-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
|
|
IL317134A
(en)
|
2016-12-21 |
2025-01-01 |
Teneobio Inc |
An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
|
|
EP3565841A1
(en)
|
2017-01-06 |
2019-11-13 |
Crescendo Biologics Limited |
Single domain antibodies to programmed cell death (pd-1)
|
|
MA47604A
(fr)
|
2017-02-21 |
2020-01-01 |
Regeneron Pharma |
Anticorps anti-pd-1 pour le traitement du cancer du poumon
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
JOP20190222A1
(ar)
*
|
2017-04-11 |
2019-09-24 |
Zymeworks Inc |
الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
|
|
CN110945026B
(zh)
|
2017-06-20 |
2024-03-19 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
AR112257A1
(es)
|
2017-06-21 |
2019-10-09 |
Gilead Sciences Inc |
Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
BR112020000127A2
(pt)
|
2017-07-06 |
2020-07-07 |
Regeneron Pharmaceuticals, Inc. |
método para selecionar um hidrolisado de soja, e, glicoproteína
|
|
GB201711068D0
(en)
|
2017-07-10 |
2017-08-23 |
Crescendo Biologics Ltd |
Therapeutic molecules binding PSMA
|
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
WO2019022671A1
(en)
*
|
2017-07-28 |
2019-01-31 |
National University Of Singapore |
BIOMOLECULAR COMPOSITES COMPRISING MODIFIED CELLULAR PHANTOMS
|
|
KR102794369B1
(ko)
|
2017-08-01 |
2025-04-15 |
에이비 테라퓨틱스 인코퍼레이티드 |
이중특이 항체 및 그의 용도
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
EP3710478A1
(en)
|
2017-11-13 |
2020-09-23 |
Crescendo Biologics Limited |
Molecules that bind to cd137 and psma
|
|
IL275426B2
(en)
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
MX2020006639A
(es)
|
2017-12-22 |
2020-09-14 |
Regeneron Pharma |
Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
|
|
CN111683966B
(zh)
|
2017-12-22 |
2023-07-11 |
特尼奥生物股份有限公司 |
与cd22结合的重链抗体
|
|
BR112020013336A2
(pt)
|
2018-01-31 |
2020-12-01 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
IL325995A
(en)
|
2018-02-08 |
2026-03-01 |
Genentech Inc |
Bispecific antigen binding molecules and methods of use
|
|
GB201802573D0
(en)
|
2018-02-16 |
2018-04-04 |
Crescendo Biologics Ltd |
Therapeutic molecules that bind to LAG3
|
|
WO2019168774A1
(en)
|
2018-02-28 |
2019-09-06 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
IL277049B2
(en)
|
2018-03-13 |
2024-02-01 |
Zymeworks Bc Inc |
Conjugates of biparatopic anti-HER2 antibody and drug and methods of use
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
HUE065344T2
(hu)
|
2018-03-19 |
2024-05-28 |
Regeneron Pharma |
Mikrochip kapilláris elektroforézis assay-k és reagensek
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
EP3569617A1
(en)
*
|
2018-05-18 |
2019-11-20 |
Trion Research GmbH |
Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
|
|
CN110540593B
(zh)
*
|
2018-05-29 |
2022-05-17 |
上海药明生物技术有限公司 |
新型的抗cd3/抗cd20双特异性抗体
|
|
TW202504917A
(zh)
|
2018-06-21 |
2025-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
|
|
CN119264211A
(zh)
|
2018-08-27 |
2025-01-07 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
JP7511542B2
(ja)
|
2018-08-30 |
2024-07-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質複合体を特徴づけるための方法
|
|
CA3110513A1
(en)
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
CN109836502B
(zh)
*
|
2018-11-12 |
2021-09-07 |
浙江大学 |
一种双特异性抗体及其应用
|
|
WO2020150491A1
(en)
|
2019-01-16 |
2020-07-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing disulfide bonds
|
|
US12463463B2
(en)
|
2019-01-28 |
2025-11-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
CN111484555B
(zh)
*
|
2019-01-28 |
2022-07-08 |
正大天晴药业集团股份有限公司 |
新型双特异性cd3/cd20多肽复合物
|
|
WO2020156405A1
(en)
*
|
2019-01-28 |
2020-08-06 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel bispecific cd3/cd20 polypeptide complexes
|
|
KR20210126641A
(ko)
|
2019-02-12 |
2021-10-20 |
리제너론 파아마슈티컬스, 인크. |
보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
|
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2020206330A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
WO2020231992A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
WO2021061790A1
(en)
|
2019-09-24 |
2021-04-01 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
CA3158119A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
CN115398236B
(zh)
|
2020-01-21 |
2024-06-11 |
瑞泽恩制药公司 |
用于糖基化的蛋白质的电泳的去糖基化方法
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
KR20230005936A
(ko)
|
2020-05-01 |
2023-01-10 |
리제너론 파아마슈티컬스, 인크. |
치료 단백질에 대한 중화 항체 검정
|
|
MX2022013797A
(es)
|
2020-05-08 |
2022-11-30 |
Genmab As |
Anticuerpos biespecificos contra cd3 y cd20.
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
CA3217391A1
(en)
|
2020-07-27 |
2022-02-03 |
Youwei ZHU |
Formulation of novel bispecific anti-cd3/cd20 polypeptide complex
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
WO2022047108A1
(en)
|
2020-08-31 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
CA3189883A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
CA3190376A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
US20240034812A1
(en)
|
2020-09-10 |
2024-02-01 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
KR20230066040A
(ko)
|
2020-09-10 |
2023-05-12 |
젠맵 에이/에스 |
만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체
|
|
CN116782933A
(zh)
|
2020-09-10 |
2023-09-19 |
健玛保 |
用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
|
|
JP2023544164A
(ja)
*
|
2020-10-02 |
2023-10-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイトカイン放出症候群の低減を伴うがんを治療するための抗体の組合せ
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
AU2021374594B2
(en)
|
2020-11-04 |
2026-03-05 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
|
|
WO2022115588A1
(en)
|
2020-11-25 |
2022-06-02 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
KR20230121854A
(ko)
|
2020-12-17 |
2023-08-21 |
리제너론 파아마슈티컬스, 인크. |
단백질-캡슐화 마이크로겔의 제작
|
|
MX2023008527A
(es)
|
2021-01-20 |
2023-07-28 |
Regeneron Pharma |
Metodos para mejorar el valor proteico en cultivo celular.
|
|
AU2022214319A1
(en)
|
2021-01-28 |
2023-08-03 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating cytokine release syndrome
|
|
JP2024512299A
(ja)
|
2021-03-03 |
2024-03-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質の粘度を定量及び変更するためのシステム及び方法
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
MX2023010567A
(es)
|
2021-03-12 |
2023-09-21 |
Genmab As |
Variantes de anticuerpos no activadoras.
|
|
AU2022243005A1
(en)
|
2021-03-26 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4337330A1
(en)
|
2021-05-14 |
2024-03-20 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
US12227574B2
(en)
|
2021-06-17 |
2025-02-18 |
Amberstone Biosciences, Inc. |
Anti-CD3 constructs and uses thereof
|
|
US20230077710A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
|
|
CA3232463A1
(en)
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
|
CA3230984A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Systems and methods of ph modeling and control
|
|
WO2023059803A1
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Ph meter calibration and correction
|
|
TW202330104A
(zh)
|
2021-10-26 |
2023-08-01 |
美商再生元醫藥公司 |
用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
|
|
EP4437003A1
(en)
|
2021-11-24 |
2024-10-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
|
|
US20230312718A1
(en)
|
2022-01-07 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc |
Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies
|
|
IL315405A
(en)
|
2022-03-17 |
2024-11-01 |
Regeneron Pharma |
Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies
|
|
KR20240164561A
(ko)
|
2022-03-18 |
2024-11-19 |
리제너론 파아마슈티컬스, 인크. |
폴리펩타이드 변종을 분석하기 위한 방법 및 시스템
|
|
EP4507790A1
(en)
|
2022-04-11 |
2025-02-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
US11958906B2
(en)
|
2022-04-13 |
2024-04-16 |
Genentech, Inc. |
Pharmaceutical compositions of mosunetuzumab and methods of use
|
|
AU2022456952A1
(en)
|
2022-05-02 |
2024-11-28 |
Regeneron Pharmaceuticals, Inc. |
Biochemical assays for therapeutic proteins
|
|
EP4522657A1
(en)
|
2022-05-12 |
2025-03-19 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
WO2023224912A1
(en)
|
2022-05-16 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
US20230416396A1
(en)
|
2022-05-18 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
|
IL318426A
(en)
|
2022-08-02 |
2025-03-01 |
Regeneron Pharma |
Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies
|
|
WO2024040206A2
(en)
*
|
2022-08-19 |
2024-02-22 |
Eli Lilly And Company |
Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody
|
|
TW202435942A
(zh)
|
2022-12-16 |
2024-09-16 |
美商里珍納龍藥品有限公司 |
評估層析管柱完整性的方法及系統
|
|
EP4655595A1
(en)
|
2023-01-25 |
2025-12-03 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
CN120857940A
(zh)
|
2023-02-17 |
2025-10-28 |
瑞泽恩制药公司 |
对cd3/taa双特异性抗体有反应的诱导型nk细胞
|
|
EP4669963A2
(en)
|
2023-02-22 |
2025-12-31 |
Regeneron Pharmaceuticals, Inc. |
SYSTEM FITNESS PARAMETERS AND COLUMN AGING
|
|
CU20250022A7
(es)
*
|
2023-03-10 |
2026-04-09 |
Biocad Joint Stock Co |
Anticuerpo biespecífico que se une específicamente al cd3 y al antígeno tumoral
|
|
US20240366471A1
(en)
|
2023-05-01 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
KR20260049559A
(ko)
|
2023-08-02 |
2026-04-14 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-PSMA x 항-CD28 항체를 이용한 투명 세포 신세포 암종의 치료 방법
|
|
IL325956A
(en)
|
2023-08-02 |
2026-03-01 |
Regeneron Pharma |
Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28
|
|
WO2025054406A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
US20250095773A1
(en)
|
2023-09-18 |
2025-03-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
US20250129117A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
US20250145662A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
TW202539732A
(zh)
|
2023-11-29 |
2025-10-16 |
美商再生元醫藥公司 |
以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
|
|
TW202542187A
(zh)
|
2023-12-12 |
2025-11-01 |
美商再生元醫藥公司 |
以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025160324A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025171124A1
(en)
|
2024-02-07 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
TW202602489A
(zh)
|
2024-03-15 |
2026-01-16 |
美商再生元醫藥公司 |
作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
|
|
WO2025240287A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
|
|
WO2025244973A1
(en)
|
2024-05-20 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
WO2026006492A2
(en)
|
2024-06-25 |
2026-01-02 |
Ypsilon Therapeutics, Inc. |
Anti-prame/hla-a2 antibodies and uses thereof
|
|
WO2026006495A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-wt1/hla-a2 antibody and uses thereof
|
|
WO2026015612A1
(en)
|
2024-07-10 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating smarcb1-deficient cancers
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
WO2026059917A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors
|
|
WO2026059919A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors
|
|
WO2026059923A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator
|
|
WO2026059920A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors
|
|
WO2026059921A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|